Stocks Health care DTIL
NASDAQ · Health carePrecision Biosciences Inc (DTIL)
Precision Biosciences Inc brought in $45M of revenue over the twelve months to September 30, 2026, up 6,353.0% from a year earlier. It posted a net loss of $38.5M. In fiscal 2025 capital spending exceeded operating cash flow by $65.9M. At September 30, 2026 it held $81.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Precision Biosciences Inc
- Net worth
- Precision Biosciences Inc has a market value (market cap) of $267.2M at the latest share price, and shareholders' equity of $51.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $34.3M (-50.1% year on year), with a net loss of $45.7M. Over the 12 months to September 30, 2026: revenue $45M, net loss $38.5M.
- Cash flow
- In fiscal 2025 operations used $65.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Precision Biosciences Inc's next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Precision Biosciences Inc does
Precision Biosciences Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker DTIL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $34.3M | -$45.7M | -$3.56 | -$65.9M |
| 2024 | $68.7M | $7.2M | $1.04 | -$58.7M |
| 2023 | $48.7M | -$61.3M | -$15.96 | -$86.1M |
| 2022 | $25.1M | -$111.6M | -$38.10 | -$49.1M |
| 2021 | $115.5M | -$30.6M | -$15.60 | -$15.9M |
| 2020 | $24.3M | -$109M | -$62.70 | -$92.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where DTIL ranks in Health care
Latest SEC filings
What Precision Biosciences Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Other event 8-K
- November 6, 2026Other event 8-K
- November 5, 2026
- November 3, 2026Passive stake changed SCHEDULE 13G/A
- November 3, 2026
- November 3, 2026
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- August 24, 2026Passive stake changed SCHEDULE 13G/A
- August 24, 2026
- August 7, 2026
Insider trades
What the people running Precision Biosciences Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $29.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 28, 2026 | Frankel StanleyDirector | Bought | 1,000 | $6K |
| September 25, 2026 | Germano Geno JDirector | Bought | 2,609 | $16.4K |
| September 25, 2026 | Brown MelindaDirector | Bought | 1,135 | $7.1K |
| May 20, 2026 | Germano Geno JDirector | Exercised options | 21,000 | - |
| May 20, 2026 | Pire Shari LisaDirector | Exercised options | 21,000 | - |
| May 20, 2026 | Brown MelindaDirector | Exercised options | 21,000 | - |
| May 20, 2026 | Frankel StanleyDirector | Exercised options | 21,000 | - |
| May 20, 2026 | Buehler KevinDirector | Exercised options | 21,000 | - |
Who owns DTIL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Matthew Smith13G, passive with 4 related filers | 9.4% | August 14, 2025 |
| Aberdeen Group plc13G, passive with 1 related filers | 8.88% | January 27, 2026 |
| Bleichroeder LP13G, passive with 2 related filers | 8.21% | February 13, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 5.9% | November 14, 2024 |
| Octagon Capital Advisors LP13G, passive with 2 related filers | 5.73% | November 3, 2026 |
| Lynx1 Capital Management LP13G, passive with 1 related filers | 5.4% | July 20, 2026 |
| BlackRock, Inc.13G, passive | 5.01% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 95 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Aberdeen Group plc | 2,230,178 | 0 |
| Bleichroeder LP | 2,018,190 | +355,690 |
| Octagon Capital Advisors LP | 1,350,000 | -886,732 |
| Boothbay Fund Management, LLC | 1,346,004 | +279,954 |
| BlackRock, Inc. | 1,172,873 | +973,112 |
| Vanguard Capital Management LLC | 1,116,241 | +205,501 |
| Lynx1 Capital Management LP | 950,466 | -34,647 |
| Driehaus Capital Management LLC | 946,707 | -48,664 |
| Empery Asset Management, LP | 776,093 | -1,192,786 |
| Affinity Asset Advisors, LLC | 646,576 | +48,630 |
| Geode Capital Management, LLC | 620,981 | +333,891 |
| Mackenzie Financial Corp | 480,997 | new |
| State Street Corp | 427,325 | +354,383 |
| ArrowMark Colorado Holdings LLC | 274,140 | +95,000 |
| Corient Private Wealth LP | 245,058 | +101,206 |
| Two Sigma Investments, LP | 237,863 | -69,927 |
| Northern Trust Corp | 190,188 | +114,119 |
| Jpmorgan Chase & Co | 180,452 | +180,444 |
| Vanguard Fiduciary Trust Co | 166,538 | +10,912 |
| Vanguard Portfolio Management LLC | 161,782 | new |
Insiders
9 insiders reported holding 766,274 shares in total, about $7.4M at the last price.
| Holder | Shares |
|---|---|
| Amoroso MichaelPresident and CEO, Director | 243,392 |
| Kelly John AlexanderChief Financial Officer | 125,883 |
| Smith J. JeffersonChief Research Officer | 121,926 |
| Scimeca DarioGeneral Counsel and Secretary | 56,457 |
| Buehler KevinDirector | 49,137 |
| Germano Geno JDirector | 47,492 |
| Brown MelindaDirector | 45,481 |
| Frankel StanleyDirector | 41,478 |
| Pire Shari LisaDirector | 35,028 |
Questions about DTIL
What does Precision Biosciences Inc do?
Precision Biosciences Inc is a company in the Health care sector, listed on NASDAQ as DTIL. Its shares trade on NASDAQ under the ticker DTIL.
What is Precision Biosciences Inc's net worth?
Precision Biosciences Inc has a market value (market cap) of $267.2M at the latest share price, and shareholders' equity of $51.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Precision Biosciences Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $38.5M on revenue of $45M.
How much revenue does Precision Biosciences Inc make?
Over the twelve months to September 30, 2026 Precision Biosciences Inc reported revenue of $45M. That is 6,353.0% more than a year earlier.
When did Precision Biosciences Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the other event from November 9, 2026.
When is Precision Biosciences Inc's next earnings report?
Precision Biosciences Inc's next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DTIL with
Follow DTIL
Get an email when Precision Biosciences Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Precision Biosciences Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.